This article is more than 5 years old. Information may no longer be current.
Benefits of CGM in infants, toddlers mixed
Click Here to Manage Email Alerts
ADA 71st Scientific Sessions
New data suggest that continuous glucose monitoring in children with type 1 diabetes who are younger than 4 years provided the ability to document glycemic control during a 6-month study period without frequent hypoglycemic episodes.
Researchers monitored the safety and efficacy of two CGM devices (Freestyle Navigator, Abbott; Paradigm, Medtronic) in 15 boys and eight girls with type 1 diabetes (mean age, 3 years; mean HbA1c, 8%). At baseline, 10 were using an insulin pump and 13 were receiving multiple daily injections.
At 6 months, follow-up data were available for 20 children. Among them, more than 40% were using CGM on a near-daily basis. During the final month of the study, nine used CGM at least 6 days per week; four used CGM 3 to 5 days per week; and seven used CGM fewer than 3 days per week.
According to results collected from the devices, hyperglycemia was usually present for more than half of the day; biochemical hypoglycemia rarely occurred. Participants experienced no severe skin reactions. HbA1c, however, did not change from baseline after 6 months of CGM use.
For more information:
- Tsalikian E. 1219-P. Presented at: American Diabetes Association’s 71st Scientific Sessions; June 24-28, 2011; San Diego, Calif.
 |
Follow EndocrineToday.com on Twitter. |